Cellular activation by thromboxane A2 and 8-EPI-PGF2 alpha.
Pratico
D
D
Dept. of Medicine and Experimental Therapeutics, University College, Dublin, Ireland.
O'Mahony
D
D
Lawson
J
J
Kinsella
T
T
Fitzgerald
G A
GA
D000818:Animals; D001241:Aspirin / Q000494:pharmacology; D002460:Cell Line; D017868:Cyclic AMP-Dependent Protein Kinases / Q000378:metabolism; D015237:Dinoprost / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D017354:Point Mutation; D011493:Protein Kinase C / Q000378:metabolism; D017482:Receptors, Thromboxane / Q000096:biosynthesis / Q000737:chemistry / Q000502:physiology*; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000737:chemistry; D013928:Thromboxane A2 / Q000494:pharmacology*; D014162:Transfection; D014662:Vasoconstrictor Agents / Q000494:pharmacology
D017482:Receptors, Thromboxane; D011994:Recombinant Proteins; D014662:Vasoconstrictor Agents; C075750:8-epi-prostaglandin F2alpha; D013928:Thromboxane A2; D015237:Dinoprost; D017868:Cyclic AMP-Dependent Protein Kinases; D011493:Protein Kinase C; D001241:Aspirin